Kyverna Therapeutics, Inc. (KYTX) Stock Statistics & Valuation Metrics

Kyverna Therapeutics, Inc. has a market cap or net worth of $579.01M. The enterprise value is $324.46M.

Kyverna Therapeutics, Inc. has 60,439,890 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kyverna Therapeutics, Inc.’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -64.99%.

The current PE Ratio of Kyverna Therapeutics, Inc. is ―. Kyverna Therapeutics, Inc.’s PEG ratio is -0.28.

In the last 12 months, Kyverna Therapeutics, Inc. had revenue of 0.00 and earned -161.31M in profits. Earnings per share was -3.64.

In the last 12 months, operating cash flow was -153.71M and capital expenditures -591.00K, giving a free cash flow of -154.30M billion.

Kyverna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Kyverna Therapeutics, Inc. upcoming earnings date is May 19, 2026, After Close (Confirmed).

Kyverna Therapeutics, Inc. as a current ratio of 7.75, with Debt / Equity ratio of 12.50%

In the past 12 months, Kyverna Therapeutics, Inc. has paid 0.00 in taxes.

Kyverna Therapeutics, Inc. EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -2.09.

Kyverna Therapeutics, Inc. has $279.25M in cash and marketable securities with $29.03M in debt, giving a net cash position of $250.22M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Kyverna Therapeutics, Inc. is $27.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy